High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection
about
Untangling tau imagingCharacteristics of Tau and Its Ligands in PET ImagingImaging pathological tau in atypical parkinsonian disordersComparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807PET Radioligands for Imaging of Tau Pathology: Current Status.Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.Non human primate models for Alzheimer's disease-related research and drug discovery.Late-stage [(18)F]Fluorination: New Solutions to Old ProblemsNew advances in tau imaging in parkinsonism.Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies.Automated synthesis of PET radiotracers by copper-mediated 18 F-fluorination of organoborons: Importance of the order of addition and competing protodeborylation.Prolonged In Vivo Retention of a Cathepsin D Targeted Optical Contrast Agent in a Mouse Model of Alzheimer's Disease.Novel PET/SPECT probes for imaging of tau in Alzheimer's disease.Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants.Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences.
P2860
Q26739091-E57BD3C5-9423-40F7-98BF-4B9E24ED8F5FQ26769952-475203A6-0BC0-4F96-AEF1-00631D3D1F99Q26823039-64422DB1-EE33-4BB1-BC2C-2EF4F8A21011Q33795224-736D653B-1C61-46BB-8CC8-BC4CDFBA0AA9Q36241261-A9FBF580-EDE0-45F4-85A9-F45DA4A452ADQ38669442-26F81B14-6E36-4932-9C12-30E8D5FCE856Q38783343-35930A1E-EC1F-4D96-B75D-40347A00B620Q42615427-8DC50CE2-1CA4-4478-A338-D2E62035F899Q47329627-A04EA9BC-E325-4D5D-B385-ECE169E5D56FQ47330246-B02CE82E-3452-4D8F-B636-43E0E4854206Q47824973-5ADF7433-2A92-4251-B7D7-AE2978BC56DBQ48294334-AB46041F-15E6-4C30-A6B1-D46AC52BF040Q50436669-73DEE596-2B41-4E62-B1FE-FB6B33EAC8C5Q53014962-853F70F5-858C-423B-BBAC-3C7A153AC57DQ55311648-89E67CFA-8F4D-4D92-A876-144BCDBA6757Q55362855-D2B5B485-3B41-499A-B2FF-421285ADDE9A
P2860
High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
High affinity radiopharmaceuti ...... evaluation, and lead selection
@ast
High affinity radiopharmaceuti ...... evaluation, and lead selection
@en
High affinity radiopharmaceuti ...... evaluation, and lead selection
@nl
type
label
High affinity radiopharmaceuti ...... evaluation, and lead selection
@ast
High affinity radiopharmaceuti ...... evaluation, and lead selection
@en
High affinity radiopharmaceuti ...... evaluation, and lead selection
@nl
prefLabel
High affinity radiopharmaceuti ...... evaluation, and lead selection
@ast
High affinity radiopharmaceuti ...... evaluation, and lead selection
@en
High affinity radiopharmaceuti ...... evaluation, and lead selection
@nl
P2093
P2860
P356
P1476
High affinity radiopharmaceuti ...... evaluation, and lead selection
@en
P2093
Brian G Hockley
Carole A Quesada
Garrett M Carpenter
Kirk A Frey
Maria V Fawaz
Melissa E Rodnick
Michael R Kilbourn
Phillip Sherman
Roger L Albin
Timothy J Desmond
P2860
P304
P356
10.1021/CN500103U
P407
P577
2014-06-16T00:00:00Z